Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.56 |
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | STS | P08842 | 1/20 | 0.54 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3966170 | 0.99 | CHRM4 (0.55) | CHRM4ACHEKDM4EALDH1A1TP53 | |
| SCHEMBL3570582 | 0.95 | ACHE (0.61) | CHRM4ACHEKDM4EALDH1A1TP53 | |
| SCHEMBL642727 | 0.93 | JAK2 (0.54) | CHRM4ACHEKDM4EALDH1A1TP53 | |
| SCHEMBL642728 | 0.93 | JAK2 (0.54) | CHRM4ACHEKDM4EALDH1A1TP53 | |
| SCHEMBL7362773 | 0.92 | CHRM4 (0.59) | CHRM4ACHEKDM4EALDH1A1TP53 | |
| SCHEMBL9058559 | 0.90 | KMT2A (0.58) | CHRM4ACHEKDM4EALDH1A1TP53 | |
| SCHEMBL32665859 | 0.89 | TP53 (0.53) | CHRM4ACHEKDM4EALDH1A1TP53 | |
| SCHEMBL643291 | 0.89 | ALDH1A1 (0.48) | CHRM4ACHEKDM4EALDH1A1TP53 | |
| SCHEMBL13443092 | 0.88 | ACHE (0.54) | ACHEKDM4EALDH1A1TP53THRB | |
| SCHEMBL2862442 | 0.87 | ALDH1A1 (0.60) | CHRM4KDM4EALDH1A1TP53THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | MORPHOCHEM AKTIENGESELLSCHAFT FUR KOMBINATORISCHE CHEMIE (DE) | 2010-12-23 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-1440976-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-07-28 | — | — | EP | disclosed |
| EP-0927192-B1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | disclosed |
| US-20020082262-A1 | Substituted bicyclic compounds for treating multidrug resistance | PROCTER & GAMBLE COMPANY, THE | 2002-06-27 | — | — | US | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
| US-5814636-A | TREATMENT AND PROPHYLAXIS OF THROMBOTIC DISEASES | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1998-09-29 | — | — | US | disclosed |
| CN-1134695-A | Novel compound having platelet aggregation inhibitor effect | MEIJI SEIKA CO (JP) | 1996-10-30 | — | — | CN | disclosed |
| EP-0721941-A1 | NOVEL COMPOUND HAVING PLATELET AGGREGATION INHIBITOR EFFECT | MEIJI SEIKA KABUSHIKI KAISHA (JP) | 1996-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | CHRM4 20/4885ACHE 408/4885KDM4E 2890/4885 |
| US-20020082262-A1 | Substituted bicyclic compounds for treating multidrug resistance | ABCB1, ABCC1, ABCB11 | CHRM4 4200/4885ACHE 3041/4885KDM4E 4039/4885 |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | CHRM4 27/4885ACHE 438/4885KDM4E 2891/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | CHRM4 27/4885ACHE 474/4885KDM4E 2928/4885 |
| US-20100324030-A1 | 5-Quinoline derivatives having an anti-bacterial activity | TOP2A, TOP1, TOP2B | CHRM4 4327/4885ACHE 700/4885KDM4E 1219/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | CHRM4 27/4885ACHE 438/4885KDM4E 2891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.